Comparison of the Efficacy and Safety of Cyp2c19 Gene-guided Oral Administration of Different P2Y12 Inhibitors in Elderly Patients with Acute Coronary Syndrome

Binbin Zhen; Jianhua Zhang

doi:10.54097/m91jrv47

Authors

Binbin Zhen
Jianhua Zhang

DOI:

https://doi.org/10.54097/m91jrv47

Keywords:

Acute coronary syndrome, Cyp2c19 gene, Clopidogrel, Tegretol, Ischemic events.

Abstract

Objective To explore the survival prognosis and safety analysis of the cyp2c19 gene-guided ACS elderly patient group using Tegretol and Clopidogrel. Methods Three hundred and eighty-five ACS patients aged ≥65 years were selected, tested for polymorphisms in the cyp2c19 gene, and divided into two groups according to the oral P2Y12 receptor inhibitor: 320 patients in the clopidogrel group and 165 patients in the tegretol group. Patients were followed up for 1 year after discharge from the hospital, with the primary end point being a composite end point of adverse cardiovascular events including cardiac death, nonfatal infarction, or absence of stroke, and the secondary end point including unstable angina, in-stent stenosis, target vessel revascularization, and all-cause mortality, as well as bleeding events. Results The 1-year rate of ischemic events was lower in patients treated with tegretol compared with the clopidogrel group [28.5% (47/165) versus 26.3% (84/320), P = 0.599], and the difference in the 1-year rate of BARC 2, 3, and 5 events between the two groups was not statistically significant [6.0% (10/165) versus 3.4% (11/320), P = 0.179]. P = 0.179]. Conclusion In elderly patients with cyp2c19-directed ACS, there was no significant difference in survival prognosis, ischemic events, or bleeding risk between tegretol and clopidogrel at 1 year.

Downloads

Download data is not yet available.

References

M. Valgimigli, H. Bueno, R.A. Byrne, et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J, 39 (2018), pp. 213-260

Schomig, F.J. Neumann, A. Kastrati, et al.A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents N Engl J Med, 334 (1996), pp. 1084-1089

P.A. Gurbel, K.P. Bliden, B.L. Hiatt, C.M. O’Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation, 107 (2003), pp. 2908-2913

J.L. Mega, T. Simon, J.P. Collet, et al.Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA, 304 (2010), pp. 1821-1830

A.R. Shuldiner, J.R. O’Connell, K.P. Bliden, et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA, 302 (2009), pp. 849-857

W. Hochholzer, D. Trenk, M.F. Fromm, et al.Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol, 55 (2010), pp. 2427-2434

M.J. Price, S.S. Murray, D.J. Angiolillo, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study J Am Coll Cardiol, 59 (2012), pp. 1928-1937

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.

Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.

SD Wiviott, E Braunwald, CH McCabe, et al.Prasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med, 357 (2007), pp. 2001-2015

L Wallentin, RC Becker, A Budaj, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med, 361 (2009), pp. 1045-1057

R Piccolo, G Magnani, S Ariotti, et al.Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial EuroIntervention, 13 (2017), pp. 78-86

J Chandrasekhar, U Baber, S Sartori, et al.Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS studyClin Res Cardiol (2020) published online January 8.

Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC Guidelines on dual antiplatelet therapy: JACC Guideline comparison[J]. J Am Coll Cardiol, 2018, 72(23Pt A): 2915-2931. DOI: 10.1016/j.jacc.2018.09.057.

Gorog DA, Yamamoto J, Saraf S, et al. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the "Japanese paradox"[J]. Int J Cardiol, 2011, 152(1): 43-48. DOI: 10.1016/j.ijcard.2010.07.002.

Thomas MP, Moscucci M, Smith DE, et al. Outcome of contemporary percutaneous coronary intervention in the elderly and the very elderly: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium[J]. Clin Cardiol, 2011, 34(9): 549-554. DOI: 10.1002/clc.20926.